Newswise — LEXINGTON, Ky. (Feb. 9, 2022) — Recent findings in the laboratory of University of Kentucky Markey Cancer Center researcher Christine Brainson, Ph.D., could lead to promising treatments for two molecular subtypes of lung cancer.

Cancer is caused by certain changes to genes that control the way our cells function, especially how they grow and divide. Brainson, an assistant professor in the College of Medicine’s Department of Toxicology and Cancer Biology, studies lung cancers with specific abnormal genes to define new potential therapy options.

Brainson’s lab works closely with Markey’s Molecular Tumor Board (MTB), which analyzes the genes in tumors to help oncologists choose precision cancer therapies tailored to each patient’s individual needs. This information helps direct research and development of new therapies that target the types of cancers found at Markey and throughout Kentucky.

Recently-published studies from the Brainson Lab reveal more about two genetic subclasses of lung cancer – EGFR-driven and PIK3CA-driven lung cancers – and suggest promising treatment options for both.

Research published in Advanced Science focuses on EGFR-driven adenocarcinoma, a type of non-small cell lung cancer that happens in both smokers and non-smokers that remains a leading cause of cancer death in the U.S. One of the major treatment options for EGFR-driven adenocarcinomas targets the epidermal growth factor receptor (EGFR) protein using a therapy called tyrosine kinase inhibitors (TKIs). However, patients often develop drug resistance to TKI treatment.

Brainson’s research suggests that combining TKI treatment with additional targeted therapies could be more effective for patients that have resistance to TKIs.

Her team activated EGFR in the lung cells of a mouse model, which created tumors in the lower parts of the lungs. They next tested if different cells in the lung could ‘become’ tumors when EGFR was activated using a system to grow the cells outside the mouse. These groups of cells, called tumoroids, allowed the researchers to ask which cells could give rise to which types of tumors and what the earliest events in the tumor initiation process were. They used these tumoroids to examine drug responses to different TKIs and targeted therapies and confirmed pathways activated in the mouse model were consistent with human cancer cells.

“This suggested that patients with TKI resistance may have similar EGFR-driven tumors, which have distinct drug vulnerabilities,” Brainson said. “So combining TKIs with therapies to target these cells could make the tumors more sensitive to TKI treatment.”

Another study published in Cancer Letters focused on a mutation in the gene PIK3CA, which is part of the PI3 kinase complex and a common mutation in cancer including non-small cell lung cancers. While PI3 kinase inhibitors have been developed to treat this genetic subclass of lung cancer, they are not as effective as initially hoped, Brainson says.

Brainson’s team built a PIK3CA tumor model to test different therapies and found that PI3K inhibitors were more effective when combined with another drug called a EZH2 inhibitor. Both copanlisib, the PI3K inhibitor tested, and tazemetostat, the EZH2 inhibitor, are already FDA-approved. This eases the transition to clinical research, Brainson says.

Brainson is now working with the lung translational group to understand how findings from both studies could be used to guide clinical trials.

Research reported in this publication was supported in part by the National Cancer Institute of the National Institutes of Health under Award Numbers K22CA201036 and R01CA237643, and the National Institute of General Medical Sciences of the National Institutes of Health under Award Number P20GM12132703. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.


The University of Kentucky is increasingly the first choice for students, faculty and staff to pursue their passions and their professional goals. In the last two years, Forbes has named UK among the best employers for diversity, and INSIGHT into Diversity recognized us as a Diversity Champion four years running. UK is ranked among the top 30 campuses in the nation for LGBTQ* inclusion and safety. UK has been judged a “Great College to Work for" three years in a row, and UK is among only 22 universities in the country on Forbes' list of "America's Best Employers." We are ranked among the top 10 percent of public institutions for research expenditures — a tangible symbol of our breadth and depth as a university focused on discovery that changes lives and communities. And our patients know and appreciate the fact that UK HealthCare has been named the state’s top hospital for five straight years. Accolades and honors are great. But they are more important for what they represent: the idea that creating a community of belonging and commitment to excellence is how we honor our mission to be not simply the University of Kentucky, but the University for Kentucky.

Register for reporter access to contact details

Cancer Letters